FBFelipe de Galiza Barbosa

Felipe de Galiza Barbosa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Felipe de Galiza Barbosa has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Marcelo Araujo Queiroz

    Universidade de São Paulo, Sao Paulo, Brazil

    7 shared publications
  • Rafael Fernandes Nunes

    Hospital Sírio-Libanês and UnitedHealth Group, São Paulo, Brazil

    6 shared publications
  • José Flávio Gomes Marin

    Oncology Center, Hospital Sírio-Libanês, São Paulo 01308-050, Brazil

    5 shared publications
  • Carlos A. Buchpiguel

    From the Departments of Radiology (L.B.C., M.A.Q., F.G.B., R.F.N., E.C.Z., M.M.R., J.F.G.M., G.G.C., C.A.B.) and Oncology (D.J.), Hospital Sírio-Libanês, Rua Dona Adma Jafet 115, 01308-060 São Paulo, SP, Brazil; and Department of Radiology and Oncology, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil (M.A.Q., J.F.G.M., G.G.C., C.A.B.).

    3 shared publications
  • Elaine C. Zaniboni

    From the Departments of Radiology (L.B.C., M.A.Q., F.G.B., R.F.N., E.C.Z., M.M.R., J.F.G.M., G.G.C., C.A.B.) and Oncology (D.J.), Hospital Sírio-Libanês, Rua Dona Adma Jafet 115, 01308-060 São Paulo, SP, Brazil; and Department of Radiology and Oncology, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil (M.A.Q., J.F.G.M., G.G.C., C.A.B.).

    3 shared publications
  • Leandro Jonata de Carvalho Oliveira

    Grupo Brasileiro de Estudos em Câncer de Mama (GBECAM), São Paulo, Brazil

    3 shared publications

Latest Publications

  • Open Access

    PET/CT Imaging in Melanoma: Review of Current Evidence and Clinical Applications

    by Vanessa Anne Mohr-Bell Giachetti, Isabela Paulino Serur, Felipe de Galiza Barbosa, Beatriz Mendes Awni Cidale, Gabriela Franco Katz, Rodrigo Ramella Munhoz

    Melanoma is regarded as a highly aggressive skin cancer due to its potential for early metastasis and poor outcomes in advanced stages. Early detection, accurate staging, follow-up imaging, and assessment of treatment response are critical for improving survival rates in melanoma patients. Positron-emission tomography/computed tomography (PET/CT), particularly utilizing 18F-fluorodeoxyglucose (18F-FDG), has become a gold standard imaging modality in the comprehensive management of melanoma. This review critically examines the current literature on the utility of PET/CT in melanoma, focusing on its diagnostic and prognostic role, current indications and rational use. By synthesizing evidence from recent studies, this article highlights the strengths and limitations of PET/CT in clinical practice and explores future directions for research in the field.

  • Prostate-Specific Membrane Antigen PET/Computed Tomography

    by Larissa Bastos Costa, Renata Moreira, Priscilla Romano Gaspar, Felipe de Galiza Barbosa

  • Open Access

    Silicone gel migration masquerading as metastatic breast cancer

    by Felipe Magaldi de Carvalho, Leandro Jonata Carvalho Oliveira, Carlos Shimizu, Felipe de Galiza Barbosa, Leonardo de Abreu Testagrossa, Max Senna Mano

    We report the case of a 72-year-old patient with stage III breast cancer who presented with multiple pulmonary nodules incidentally detected on computed tomography (CT). Further investigation using positron emission tomography (PET) revealed additional fluorodeoxyglucose-avid (FDG) chest wall lesions and widespread lymphadenopathy (axillary, retropectoral, supraclavicular, pulmonary hilar, and mediastinal), all highly suggestive of recurrent cancer ( and ). […] Silicone gel migration masquerading as metastatic breast cancer

  • Open Access

    Silicone gel migration masquerading as metastatic breast cancer

    by Felipe Magaldi de Carvalho, Leandro Jonata Carvalho Oliveira, Carlos Shimizu, Felipe de Galiza Barbosa, Leonardo de Abreu Testagrossa, Max Senna Mano

    We report the case of a 72-year-old patient with stage III breast cancer who presented with multiple pulmonary nodules incidentally detected on computed tomography (CT). Further investigation using positron emission tomography (PET) revealed additional fluorodeoxyglucose-avid (FDG) chest wall lesions and widespread lymphadenopathy (axillary, retropectoral, supraclavicular, pulmonary hilar, and mediastinal), all highly suggestive of recurrent cancer ( and ). […] Silicone gel migration masquerading as metastatic breast cancer

  • Open Access

    Inguinal lymph node metastases from prostate cancer: clinical, pathology, and multimodality imaging considerations

    by Sungmin Woo, Anton S. Becker, Soleen Ghafoor, Felipe de Galiza Barbosa, Yuki Arita, Hebert A. Vargas

    Objective: To investigate clinical, pathology, and imaging findings associated with inguinal lymph node (LN) metastases in patients with prostate cancer (PCa). Materials and Methods: This was a retrospective single-center study of patients with PCa who underwent imaging and inguinal LN biopsy between 2000 and 2023. We assessed the following aspects on multimodality imaging: inguinal LN morphology; extrainguinal lymphadenopathy; the extent of primary and recurrent tumors; and non-nodal metastases. Imaging, clinical, and pathology features were compared between patients with and without metastatic inguinal LNs. Results: We evaluated 79 patients, of whom 38 (48.1%) had pathology-proven inguinal LN metastasis. Certain imaging aspects— short-axis diameter, prostate-specific membrane antigen uptake on positron-emission tomography, membranous urethra involvement by the tumor, extra-inguinal lymphadenopathy, and distant metastases—were associated with pathology-proven inguinal LN metastases (p < 0.01 for all). Associations with long-axis diameter, fatty hilum, laterality, and uptake of other tracers on positronemission tomography were not significant (p = 0.09–1.00). The patients with metastatic inguinal LNs had higher prostate-specific antigen levels and more commonly had castration-resistant PCa (p < 0.01), whereas age, histological grade, and treatment type were not significant factors (p = 0.07–0.37). None of the patients had inguinal LN metastasis in the absence of locally advanced disease with membranous urethra involvement or distant metastasis. Conclusion: Several imaging, clinical, and pathology features are associated with inguinal LN metastases in patients with PCa. Isolated metastasis to inguinal LNs is extremely rare and unlikely to occur in the absence of high-risk imaging, clinical, or pathology features.


  • Prostate-Specific Membrane Antigen PET/Computed Tomography

    by Larissa Bastos Costa, Renata Moreira, Priscilla Romano Gaspar, Felipe de Galiza Barbosa


  • Open Access

    PSMA-PET in the early stages of prostate cancer

    by Felipe de Galiza Barbosa

    In the relentless quest to improve the management of prostate cancer, great advances have been made and improved upon in the diagnostic and therapeutic fields, especially in the last decade. After the role of magnetic resonance imaging (MRI) in locoregional evaluation had been consolidated, the advent of prostate-specific membrane antigen positron emission tomography (PSMA-PET) brought transformations that provided a new perspective on the disease and its management. This advanced imaging method has distinguished itself as a revolutionary tool, redefining the scenario of biochemical recurrence, advanced metastatic disease, and, more recently, the initial staging of patients with prostate cancer(1 1 Farolfi A, Calderoni L, Mattana F, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62:596-604. ). Its greater precision in detecting metastatic lesions has increased the accuracy of the diagnosis and guided therapeutic decisions, opening new possibilities for the customization of practice in view of the latest therapeutic advances.

  • Open Access

    PET-PSMA nas fases iniciais do câncer de próstata

    by Felipe de Galiza Barbosa

    Na busca incessante por aprimorar o manejo do câncer de próstata, na última década grandes avanços foram desenvolvidos e aprimorados tanto no âmbito terapêutico quanto no diagnóstico. Após a consolidação do papel da ressonância magnética (RM) na avaliação locorregional, a chegada da tomografia por emissão de pósitrons com antígeno de membrana específico da próstata (PET-PSMA) tem trazido transformações de um novo olhar sobre a doença e sua condução. Esse avançado método de imagem tem se destacado como uma ferramenta revolucionária, redefinindo o cenário da recidiva bioquímica, doença metastática avançada e mais recentemente no estadiamento inicial dos pacientes com câncer de próstata(1 1 Farolfi A, Calderoni L, Mattana F, et al. Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer. J Nucl Med. 2021;62:596-604. ). Sua maior precisão em detectar lesões metastáticas tem elevado a acurácia do diagnóstico e orientado decisões terapêuticas, instilando novas perspectivas na customização de conduta frente aos avanços terapêuticos vigentes.

  • Evaluation and clinical quantification of neoplastic lesions and physiological structures in TOF- versus non-TOF-PET/MRI: a pilot study

    by Felipe de Galiza Barbosa, Gaspar Delso, Konstantinos G. Zeimpekis, Edwin E. ter Voert, Martin Hüllner, Paul Stolzmann, Patrick Veit‑Haibach

    Article: Evaluation and clinical quantification of neoplastic lesions and physiological structures in TOF- versus non-TOF-PET/MRI: a pilot study - The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2021 December;65(4):386-95 - Minerva Medica - Journals

  • Open Access

    18F-FDG PETCT and 68Ga-DOTA PETCT mismatch with in vivo histopathological characterization of low-grade neuroendocrine pancreatic tumor

    by Marcello Moro Queiroz, Carlos Diego Holanda Lopes, Alessandra Corte Real Salgues, Felipe de Galiza Barbosa, Emerson Shigueaki Abe, Thales Parenti Silveira, Marcel Cerqueira Cesar Machado, Fernanda Cunha Capareli

    Background: Pancreatic neuroendocrine tumor (PNET) is a subgroup of neuroendocrine tumor (NET) that has unique biology and natural history. The histological classification has a major role in the management of this pathology, but in recent years Gallium 68 dotatate (68Ga-DOTA) scanning is at the center of a discussion about how these imaging technologies can modify clinical management of neuroendocrine tumors and how their results are correlated to Ki67 index. Method: We hereby describe a case of a patient that investigated an unspecific stable pancreatic nodule suspected of high-grade NET after evaluation with 68Ga-DOTATOC positron emission tomography—computed tomography (PETCT) and 18F-Fluorodeoxyglucose (18F-FDG) PETCT. Results: The images corroborate the hypothesis of high-grade NET based on the standard uptake value (SUV) described in both image exams (16.4 in 18FDG PETCT and 9.2 in 68Ga-DOTATOC PETCT). After surgery, the histopathological analyses revealed a localized grade 2 well-differentiated NET, Ki-67 of 4.7, glucose transport proteins 1 (GLUT1) negative by immunohistochemistry, evidencing a rare case of mismatch between the functional image and the in vivo characterization of the neoplasm. Conclusion: Functional imaging of neuroendocrine tumors with different modalities of PETCT is a well-described strategy for evaluating PNET and can dictate conducts in some cases. However, histopathological analysis is crucial to confirm the grade and prognosis related to this disease.